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ABSTRACT
Diphenylantimony(lll) and diorganotin(IV) derivatives of dithiophosphorus ligands, i.e.
Ph2SbS2PR’2 (R’= Ph, OPr-i) and R2Sn(S2PR’2)2 (R n-Bu, Ph, R’= Ph; R Ph, R’= OPr-i),
have been screened against P388 leukemia in mice. All the compounds showed marginal activity
towards this tumor system, some of them increasing the life span of the animals with more than
20%. The best results were obtained with (di-iso-pmpylphosphomdithioato)diphenylantimony(lll)
which exhibited a T/C value of 136%, at a dose of 5 mg/kg, administered on days 1,2 and 3 after
tumor transplantation.
INTRODUCTION
In recent years, the potential antitumor activity of organometallics, i.e. compounds
containing direct metal-carbon bonds, has received an increased attention, since more and
more derivatives of either transition and Main Group metals were found to exhibit interesting
inhibitory properties on animal tumor systems. Among Main Group metal compounds,
organotin(IV) derivatives occupy a top position related to their antitumor effects, with some of
them being even more active than cisplatin in in vitro tests.2-9
Interest in organoantimony(lll) compounds as potential antitumor agents arose in recent
years when diphenylantimony(lll) derivatives of dithiophosphorus ligands were reported as the
first organoantimony compounds to exhibit antitumor properties in vitro and in vivo against Ehrlich
ascites tumor.10-12 Comparative studies in this mouse tumor system, using diphenylantimony(lll)
and diphenyltin(IV) compounds containing the same dithiophosphorus ligands, pointed out that
organometallic di-iso-propylphosphorodithioates were more active than diphenylphosphino-
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dithioato analogues, and the organoantimony derivatives were more active than organotins.
Moreover, Ph2SbS2P(OPr-i)2 (5 mg/kg/day, i.p. on days 1, 3 and 5) produced an increase in
lifespan of 83% and a cure rate of 30% in mice bearing this tumor.10
Here we report the results obtained using the same compounds as above, on P388
leukemia in mice. Additionally, a dibutyltin(IV) derivative, L e. n-Bu2Sn(S2PPh2)2, was included in
the screening, since a lot of previous reports concerning the antitumor activity of organotins5,8,9
have suggested that the presence of the di-n-butyltin moiety improve the in vitro inhibitory effects
against human tumor cell lines (MCF-7 and WiDr) in comparison to analogous compounds
containing phenyl groups bound to tin.
MATERIALS AND METHODS
Animals. The DBA/2 (female, ca. 20 g) and BDF1 mice (female, 20-22 g) were provided by
Zentralinstitut for Versuchstierkunde, Hannover (FRG) and kept under conventional conditions:
3 mice per Macrolon III cage, tap water and Altmmin pellets ad libitum. Room temperature was at
about 20C; room air kept circulating 20 times/hour; a light/dark rhythm was maintained over 12
hours.
Compounds. The organometallic compounds used as antitumor agents were prepared and
purified as described earlier: bis(diphenylphosphinodithioato)diphenyltin(IV), Ph2Sn(S2PPh2)2
(compound 1 KP 1215),13 bis(di-iso-propylphosphorodithioato)diphenyltin(IV),
Ph2Sn[S2P(OPr-i)2]2 (compound 2 KP 1216),14 bis(diphenylphosphinodithioato)di-n-butyl-
tin(IV), n-Bu2Sn(S2PPh2)2 (compound :3 KP 1217),13 (di-iso-propylphosphorodithioato)-
diphenylantimony(lll), Ph2SbS2P(OPr-i)2 (compound 4 KP 1218),15 and (diphenylphosphino-
dithioato)diphenylantimony(lll), Ph2SbS2PPh2 (compound 5 KP 1219).16
In vivo experiments. P388 leukemia cells were implanted intraperitoneally into DBA/2 mice for
propagation 7 days before the experiment. The tumor cells were taken from these animals at the
begining of the experiment immediatelly after cervical dislocation. Then we implanted 106 of
these cells, suspended in 0.2 ml of physiological saline, intraperitoneally into female BDF1 mice,
body weight 20-22 g, for testing. Then the mice were arbitrarily divided into groups of each time
six animals, with one group serving as control. Therapy started 24 hours post transplantationem
(= day 1) with a single dose of the respective organometallic compounds, applied intraperitoneally
as suspension in physiological saline. As emulsifiers we used cremophorEL/propylenglycole.
Therapy was repeated on days 2 and 3.
RESULTS AND DISCUSSION
The organometallic compounds used in this screening differ not only in the nature of the
metal, organic groups bound to the metal atom, presence of aryl or alkoxy groups attached to
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phosphorus, but also by the molecular structure in solid state (Figure 1). Thus, all three
diorganotin(IV) derivatives are monomeric compounds. However, for diphenyl- and
di-n-butyltin(IV) diphenylphosphinodithioates 1 and 3 the infrared and M6ssbauer data
suggest an angular orientation of the Sn-C bonds and anisobidentate coordination of the
dithioligands,13 while for the di-iso-pmpylphosphomdithioato analogue 2, the C-Sn-C angle is
180 and the ligands are isobidentate as determined by X-ray diffmctometry.4 For both
diphenylantimony(lll) derivatives 4 and 5, the solid state structures were also investigated by the
X-ray method. The phosphomdithioato 4 has a polymeric chain structure developed through
weak Sb...S secondary bonds, the ligand acting effectivelly as a triconnective moiety.15 The
dithioligand has also a triconnective behavior in the phosphinodithioato analogue 5;, but leading
in this case to distinct dimeric units16 (Figure 1).
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Figure 1. Molecular structures of organoantimony(lll) and organotin(IV) compounds tested
as antitumor agents against P388 leukemia in mice.
The antitumor effects of the above organometallic compounds against P388 leukemia in
mice are listed in Table 1. All the diorganotin(IV) derivatives 1, 2 and 3, and the (diphenylphos-
phinodithioato)diphenylantimony(lll) 5, exhibited only marginal activity (TIC ca. 120%). Although
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the T/C value of 127% obtained for compound 3 was the best in the series of organotins, the
presence of the di-n-butyltin(IV) moiety did not spectacularly improve the antitumor properties.
As in the previous experiments on Ehrlich ascites tumor,10"12 the most active compound
was (di-iso-propylphosphomdithioato)diphenylantimony(lll). It exhibited a T/C of 136% at a dose
of 5 mg/kg, administered on days 1, 2 and 3, after tumor transplantation. However, when
increasing the dose, the toxic effect of this compound seems to be stronger, since a decreased
T/C value (i. e. 118%) was obtained.
Table 1. Test results of organoantimony(lll) and organotin(IV) compounds against P388
leukemia in mice.
Compound Day of death Dosea T/Cb
mmol/kg mg/kg (%)
Control 11, 11, 11 100
Cisplatin 20, 21, 27, 0.013 4 245
27, 33, 33
1 3, 13, 13, 0.006 5 123
14, 16, 16
2 12, 12, 13, 0.007 5 118
13, 13, 13
:3 11, 12, 14 0.0065 5 127
14, 15, 16
4 12, 12, 15 0.01 5 136
15, 15, 26
12, 13, 13, 0.02 10 118
13, 14, 14
5; 12, 12, 13, 0.(X)95 5 118
13, 13, 14
11, 12, 13, 0.019 10 123
14, 16, 16
a Therapy was carried out on days 1,2 and 3, after tumor transplantation; b T/C (%) (median
survival time of treated animals vs. median survival time of control animals)x100.
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